Podcasts about teva pharmaceutical industries ltd

Synopsis: Ivana Magovčević-Liebisch, PhD, JD, is the President and CEO of Vigil Neuroscience, a microglia-focused company dedicated to improving the lives of patients, caregivers, and families affected by rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. Ivana shares how sitting on boards of other companies has informed how she operates as CEO at Vigil. She talks about how she's seen her role evolve as the company has grown over the last three years. She discusses the importance of having diversity and diversity of thought on the leadership team. She provides her perspective on neurology as a therapeutic area, where unmet needs still exist, and the challenges and opportunities in precision-based neurology. Finally, she shares her approach to building culture at Vigil. Biography: Ivana is an accomplished pharmaceutical and biotechnology executive focused on corporate excellence and execution. She has over 20 years of senior management experience in financing, strategic partnerships, M&A, clinical development, regulatory affairs, commercialization, legal and IP strategies, and preparation and execution of operating plans. Prior to Vigil, Ivana was Executive Vice President (EVP) and Chief Business Officer at Ipsen where she was responsible for fueling the pipeline through external innovation and led the External Innovation, Business Development and Alliance Management functions. Prior to Ipsen, Ivana was EVP, Chief Strategy and Corporate Development Officer at Axcella Health, Senior VP (SVP) and Head of Global Business Development for the specialty drug business at Teva Pharmaceutical Industries Ltd. She previously worked at Dyax Corp in management roles including EVP and Chief Operating Officer where she launched the company's first drug, Kalbitor® for an orphan indication, Hereditary Angioedema, and at Transkaryotic Therapies, Inc. Ivana serves as a member of the Board of Directors for Aeglea BioTherapeutics, Inc. Ivana holds a PhD in Genetics from Harvard University and received her JD in High Technology law from Suffolk University Law School.

Synopsis: Jeremy Levin is the Chairman and CEO of Ovid Therapeutics, a company that develops medicines to treat patients with rare neurological conditions, including epilepsies and seizure-related disorders. Dr. Levin earned a PhD from Oxford and medical and surgical degrees from Cambridge before moving to the States in the late 1980s and eventually working in big pharma for companies such as Teva Pharmaceuticals and Bristol-Myers Squibb. He discusses how his formative years shaped his personal philosophy and mission to change the world for the better, the differences he experienced from running big pharma companies to early stage biotech startups, the science at Ovid and their pipeline, and his hopes for R&D in neurology over the next 10-20 years. Biography: Jeremy Levin, D.Phil, MB BChir, is chairman and chief executive officer of Ovid Therapeutics Inc. (NASDAQ: OVID), a company whose mission is to bring treatments to patients with rare neurological conditions. Dr. Levin is concurrently the chairman of Opthea (NASDAQ.OPT). Prior to founding Ovid, Dr. Levin was president and CEO of Teva Pharmaceutical Industries Ltd., (TLV: TEVA). Before Teva, Dr. Levin was a member of the executive committee Bristol-Myers Squibb Company (NYSE: BMY). In that capacity, he was the architect, lead and implementer of the String of Pearls Strategy, which transformed Bristol and facilitated the dawn and massive growth of the immuno-oncology revolution in the biopharmaceutical industry. Dr. Levin joined Bristol from Novartis (NYSE: NVS), where he was the global head of strategic alliances. He has served as a member of the board of directors of various public and private biopharmaceutical companies, including Biocon Ltd., (NSE: BIOCON), and is currently on the board of directors of Lundbeck (OMX: LUN). Dr. Levin also serves on the board and executive committee of the Biotechnology Innovation Organization (BIO) as the immediate past chairman. Dr. Levin was voted as one of the 25 most influential biotechnology leaders by Fierce Biotech, one of the top three biotechnology CEOs by The Healthcare Technology Report and one of the PharmaVoice100 CEOs in 2020. He was selected by Endpoints in 2021 as one of the 60 living pioneers of the industry. He is the recipient of the Albert Einstein Award for Leadership in Life Sciences and the B'nai B'rith Award for Distinguished Achievement. In June 2020, he edited and published the best seller “Biotechnology in the Time of Covid-19”. Dr Levin has been widely quoted and interviewed in national and international news outlets and life science industry-related publications. He believes that the role of leaders in business is to take a public stand on public policy matters as a core part of their business strategy and responsibility to shareholders, industry and society. He is committed to a public stance on key aspects of society and industry, including, but not limited to: encouraging immigration; policies that drive innovation; patient access to medicines; the principles of diversity, equity and inclusion; the primacy of medicine and science as the sole determinants to develop medical products; and the democratic right to vote for all citizens. Dr. Levin has practiced medicine at university hospitals in England, South Africa and Switzerland. Dr. Levin earned a First-Class Bachelor in Zoology, winning the University Prize, and subsequently, was awarded a master's degree and doctorate in chromatin structure, at the University of Oxford. Thereafter, he earned his medical and surgical degrees from the University of Cambridge, where he won the Kermode Prize for his work on Captopril.

Alas, we have part four in the series on Zionism hot, and ready. In this ep. we look at the influence here at home in government, top private sector positions, media, and influencers in general. I also take a look at some economic figures, arms sales, and to whom, trading with Muslim countries, and much more. Now, time to get down that Mercan rabbit hole, far beyond the mainstream!   Show Notes   Joe Biden-If there wasn't an Israel... https://youtu.be/FYLNCcLfIkM   Biden Administration https://www.timesofisrael.com/all-the-jews-biden-has-tapped-for-top-roles-in-his-new-administration/   Peter Schiff, & Adam Schiff descendants of Federal Reserve founder Jacob Schiff, Paul Moritz Warburg. https://forward.com/culture/325447/the-man-behind-the-fed/   A Few Federal Reservers   Jerome Powell Janet Yellen Stanley Fischer Vice Chair To Yellen led the Bank of Israel for 9 years. Paul Volcker Ben Bernanke Alan Greenspan Eugene Meyer -Meyer went on to purchase The Washington Post — a paper that remained in his family's hands until it was sold to Amazon's Jeff Bezos earlier this year — and in 1946 became the first president of the World Bank. Henry Morgenthau Jr. Jacob Schiff Paul Warburg   The Jewish Story Behind The Federal Reserve https://forward.com/culture/325447/the-man-behind-the-fed/   Republican Donald Trump received 24 percent of the Jewish vote in 2016, compared with 71 percent for Democrat Hillary Clinton. Atlanta Jewish Times   Trump Administration https://www.crescentcityjewishnews.com/meet-the-jews-in-donald-trumps-administration/   Ivanka Trump Most Powerful Jewish Woman https://edition.cnn.com/interactive/2017/politics/state/ivanka-trump-religion/   Obama Administration https://www.jewishvirtuallibrary.org/jews-in-the-barack-obama-administration   George W. Bush Administration https://www.jewishvirtuallibrary.org/jews-in-the-george-w-bush-administration   Bill Clinton Administration Robert 3rd Reich Robert Rubin Ruth Bader Ginsberg Michael Kantor Lawrence Summers Daniel Glickman Stephen Breyer Richard Holbrooke Samuel Berger Jack Lew Charlene Barshevsky William Cohen https://www.jewishvirtuallibrary.org/william-quot-bill-quot-clinton   Congress is now 3 times more Jewish than the United States as a whole https://www.jta.org/2019/01/03/politics/congress-is-now-3-times-more-jewish-than-the-united-states-as-a-whole   37 Jewish Members of Congress 2021 https://www.jta.org/2021/01/11/politics/here-are-the-36-jewish-members-of-congress   "Israel is the largest American aircraft carrier in the world that cannot be sunk, does not carry even one American soldier, and is located in a critical region for American national security." ~ Alexander Haig   Lib Media- Bill Maher Howard Stern Jimmy Kimmel Bill Nye Jon Stewart Jerry Springer Maury Povich Trevor Noah Jim Cramer Larry King Christopher Hitchens Sam Harris   Conservative Talk Radio- Matt Drudge Ben Shapiro Michael Savage Mark Levine Neal Boortz Michael Medved Dennis Prager Dr. Laura Ask Dr. Michael Brown Judge Judy-TV   Alt Media- Dave Rubin Weinstein Bros   Big List of Hosts- https://www.ranker.com/list/list-of-jewish-tv-and-radio-hosts/famous-jews   Big Pharma- Albert Bourla-Pfizer Leonard Schleifer-Regeneron Sol Barer, who now serves as the chairman of Teva Pharmaceuticals Industries Ltd. Israel's Teva Pharmaceutical Industries Ltd. acquired Dublin-based Allergan PLC's generic pharmaceuticals business for $40.5 billion. Martine Rothblatt-United Therapeutics Corp Alex Gorsky-J, & J   The Biden Covid Regime COVID Senior Advior, Andy Slavitt CDC Director, Rochelle P. Walensky CDC Deputy Director, Anne Schuchat CDC Chief of Staff, Sherri A. Berger, is a jew. CDC Chief Medical Officer, Mitchell Wolfe CDC Director, Washington Office, Jeff Reczek COVID Czar, Jeff Zients Moderna Vac created by Tal Zaks.   Media https://www.simpletoremember.com/articles/a/jews-in-the-media-hollywood/   Libertarians, Not including Michael Malice https://www.lewrockwell.com/lrc-blog/jewish-libertarians-2/   Neocons Who Got Is Into Iraq War https://astutenews.com/2019/05/the-25-jewish-neocons-who-got-us-into-the-iraq-war/   Cheers, and Blessings   The Odd Man Out   Their Order Is Not Our Order!

Running a team of diverse skills, and having them talk, learn, innovate and grow together while driving scientific breakthroughs? This is exactly what happens at the Satchi-Fainaro laboratory. Ronit Satchi-Fainaro is a full Professor at Tel Aviv University, where she is head of the Cancer Research & Nanomedicine Laboratory, Director of Tel Aviv University Cancer Biology Research Center, Director of the TAU Kahn 3D BioPrinting Initiative, and holds the Kurt and Herman Lion Chair in Nanosciences and Nanotechnologies. She serves on the Board of Directors of Teva Pharmaceutical Industries Ltd. and the Board of Governors of Tel Aviv University, and is a member of the Scientific Advisory Board (SAB) of the Blavatnik Center for Drug Discovery, the Israel Cancer Association, the University of Lisbon, the Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR), The Rothschild and Fulbright Fellowships Committees, several VCs, and editorial boards of scientific journals. Her multidisciplinary research laboratory focuses on basic research elucidating the mechanisms underlying the switch from cancer dormancy leading to the discovery of new molecular targets to interrupt tumor-host interactions. Her approach is followed by the design of highly selective targeting molecules integrating biology, chemistry, medicine, data science, engineering and nanotechnology to selectively guide drugs into pathological sites. Throughout, she has maintained an interest in understanding the biological rationale for the design of nanomedicines suitable for transfer into clinical testing. She has published more than 150 manuscripts, 13 book chapters, edited two books, is named inventor on 60 patents, some of which were licensed to Pharmaceutical and Biotech companies, and has delivered over 500 lectures worldwide. She founded three spin-off companies and is actively engaged in translational research with several industry partners and in science outreach. Music - Funkorama Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 3.0 Lice --- Send in a voice message: https://anchor.fm/macademia/message

My returning guest today is Dr. Jeremy Levin, Chairman and CEO of Ovid Therapeutics and the immediate past Chairman of the global Biotechnology Innovation Organization. He has been voted one of the 25 most influential people in the biopharmaceutical industry. Prior to Ovid, Dr. Levin served as President and CEO of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) the world's largest generics drug company.

Returning guest, Dr. Jeremy Levin, Chairman and CEO of Ovid Therapeutics, Inc., and former chairman of the global Biotechnology Innovation Organization (BIO) discusses the new COVID variant Delta-Plus, a virus that mutated from the highly infective Delta version, and why vaccinations are so crucial. #OvidTherapeutics #DeltaPlus #COVID Dr. Jeremy M. Levin is Chairman and CEO of Ovid Therapeutics Inc (NASDAQ:OVID), a company whose mission is to bring treatment to patients with rare neurological conditions. Dr. Levin is a former chairman of the Biotechnology Innovation Organization (BIO). Prior to founding Ovid, Dr. Levin was president and CEO of Teva Pharmaceutical Industries Ltd., (TLV: TEVA). Dr. Levin was voted as one of the twenty-five most influential biotechnology leaders by Fierce Biotech and one of the top three biotechnology CEOs in 2020 by The Healthcare Technology Report.

Mark Ramseyer, a professor at Harvard Law School, discusses the fight against extradition to Japan of two American men who are wanted there on charges that they smuggled former Nissan Motor Co. Chairman Carlos Ghosn out of the country in a box last year in his daring escape. Bloomberg's David McLaughlin discusses the decision by Teva Pharmaceutical Industries Ltd. to fight charges by the U.S. of conspiring with competitors to raise prices for generic drugs. June Grasso hosts.  Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

Mark Ramseyer, a professor at Harvard Law School, discusses the fight against extradition to Japan of two American men who are wanted there on charges that they smuggled former Nissan Motor Co. Chairman Carlos Ghosn out of the country in a box last year in his daring escape. Bloomberg's David McLaughlin discusses the decision by Teva Pharmaceutical Industries Ltd. to fight charges by the U.S. of conspiring with competitors to raise prices for generic drugs. June Grasso hosts. 

Dr. Jeremy M. Levin is Chairman and CEO of Ovid Therapeutics Inc (NASDAQ:OVID), a company whose mission is to bring treatment to patients with rare neurological conditions. Dr. Levin is concurrently the chairman of the Biotechnology Innovation Organization (BIO). Prior to founding Ovid, Dr. Levin was president and CEO of Teva Pharmaceutical Industries Ltd., (TLV: TEVA) Before Teva, Dr. Levin was member of the executive committee Bristol-Myers Squibb Company (NYSE: BMY). In that capacity he was the architect of and implemented the String of Pearls Strategy, which transformed Bristol. Dr. Levin joined BMY from Novartis (SWX: NOVN) where he was global head of strategic alliances. He has served on the board of directors of various public and private biopharmaceutical companies and is currently on the board of directors of Lundbeck (OMX: LUN). Dr. Levin was voted as one of the twenty-five most influential biotechnology leaders by Fierce Biotech and one of the top three biotechnology CEOs in 2020 by The Healthcare Technology Report. He is the recipient of the Albert Einstein Award for Leadership in Life Sciences and the B’nai B’rith Award for Distinguished Achievement. He has practiced medicine at university hospitals in England, South Africa, and Switzerland. Dr. Levin earned his bachelor’s degree in zoology and a master’s degree and doctorate in chromatin structure, at the University of Oxford, and thereafter his medical and surgical degrees from the University of Cambridge where he won the Kermode Prize for his work on Captopril. Authors of individual chapters HISTORICAL PERSPECTIVES Vicki L. Sato, Stelios Papadopoulos, Sam Waksal, Bill Sibold, Frederick Frank Q&A with a Biotech Pioneer, Brook Byers, Sol Barer PERSONAL PERSPECTIVES Michelle McMurry-Heath, Andy Plump, Kiran Mazumdar-Shaw, Karen Bernstein, Ron Cohen, Samantha Du, Cedric François THE VIEW FROM INSIDE COMPANIES George Scangos, John Young, Stéphane Bancel, Jean-Pierre Sommadossi, John V. Oyler, Paul Hastings, Christi Shaw, John Maraganore, Rachel King, Richard Pops, Deborah Dunsire BROAD LESSONS Kenneth I. Moch, Quita Highsmith, Luke Rosen, Sylvia Wulf, Philip Miller, Alex Zhavoronkov and Evelyne Bischof LEADERSHIP Jeffrey M. Solomon, Julie Louise Gerberding, Jeff Berkowitz, James Greenwood INVESTOR PERSPECTIVES Nina Kjellson, Bruce Booth, Alexander Karnal, Mark Lampert, Geoff Porges LOOKING TO THE FUTURE Peter Kolchinsky, Yaron Werber, Jeff Kindler, Otello Stampacchia

1. Organic solvents and MS susceptibility: Interaction with MS risk HLA genes 2. AAN 2018 Controversies in Neurology plenary: Andrea Leigh Haller and David Perez discuss primary caregivers for functional disorder patientsDr. Stacey Clardy talks with Dr. Anna Hedström about her paper on exposure to organic solvents and the associated risk of developing multiple sclerosis, followed by a discussion with Dr. Alberto Espay, Dr. Andrea Leigh Haller, and Dr. David Perez on who should be the primary caregivers for functional disorder patients. The second interview was originally recorded at the AAN Annual Meeting in Los Angeles.DISCLOSURES: Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR). Drs. Hedström, Leigh Haller, and Perez report no disclosures. Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; and receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation, and the NIH.

1. Non-invasive vagus nerve stimulation as acute therapy for migraine: The randomized PRESTO study2. AAN 2018 Hot Topics plenary: Michael Wilson discusses metagenomics for diagnosing CNS infectionsDr. Teshamae Monteith talks with Dr. Cristina Tassorelli about her paper on vagus nerve stimulation for treating migraine, followed by a discussion with Dr. Stacey Clardy and Dr. Michael Wilson on next-generation sequencing and diagnosing meningitis and encephalitis. The second interview was originally recorded at the AAN Annual Meeting in Los Angeles.DISCLOSURES: Dr. Monteith serves as an editorial advisory board member for Neurology Now and receives research support from the NIH. Dr. Tassorelli has served on scientific advisory boards for Allergan Inc., ElectroCore LLC, Eli-Lilly and Company, Novartis, Teva Pharmaceutical Industries Ltd; has received funding for travel or speaker honoraria from Novartis, Allergan Inc, and Teva Pharmaceutical Industries Ltd; serves on editorial boards for Journal of Headache and Pain and Frontiers in Neurology; has consulted for Allergan Inc. and Eli Lilly and Company; has received research support from Eli Lilly and Company, Novartis, Teva Pharmaceuticals, ElectroCore, and the Italian Ministry of Health; and serves as Chairman of the Committee for the Guidelines of Clinical Trials of the International Headache Society. Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR). Dr. Wilson has received research support from NIH/National Center of Advancing Translational Science (NCATS), Clinical and Translational Science Institute (CTSI), and the American Brain Foundation Clinical Research Training Fellowship.

1. Featured Article: Longitudinal analysis of impulse control disorders in Parkinson disease2. What's Trending: Frontiers in Neuroscience plenary interview from 2018 Annual MeetingThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the July 17, 2018 issue of Neurology. In the first segment, Dr. Jason Crowell talks with Dr. Alexis Elbaz about his paper on impulse control disorders in Parkinson disease. In the second part of the podcast, Dr. Alberto Espay focuses his interview with Dr. Jeff Lichtman on connectomics. The interview was recorded at the 2018 AAN Annual Meeting in Los Angeles.DISCLOSURES: Drs. Crowell and Lichtman reports no disclosures. Dr. Elbaz has received research support from Agence nationale de la recherche (ANR), Agence nationale de sécurité du médicament et des produits de santé, JPND (Joint Programme - Neurodegenerative Disease Research), Institut de santé publique (IRESP), French ministry of agriculture, and Anses (government agency for food and environment safety). Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.

Show description/summary:1) Quality improvement in neurology: Stroke and stroke rehabilitation quality measurement set update2) Neurology Today® paper on Parkinson disease and autoimmunityIn the first segment, Dr. Dan Ackerman talks with Dr. Gene Latorre about his paper on the updated quality measurement set for stroke and stroke rehabilitation. In the second part of the podcast, Dr. Alberto Espay focuses his interview with Dr. David Sulzer on Parkinson disease and autoimmunity. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.All other participants report no disclosures.

Show description/summary:1) On being sick: Musings about kindness, side effects, and slowing down2) Resident & Fellow Section Update: Annual Writing AwardIn the first segment, Dr. Alberto Espay talks with Dr. Ted Burns about his Special Editorial, “On being sick: Musings about kindness, side effects, and slowing down.” In the second part of the podcast, Dr. Andy Southerland focuses his interview with Dr. John Millichap on the annual Resident & Fellow writing award. Disclosures can be found at Neurology.org.DISCLOSURES:Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. All other participants report no disclosures.Dr. Southerland serves as Podcast Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review.Dr. Millichap has received speaker honoraria from Invitae; serves on the editorial board for Neurology and Pediatric Neurology Briefs; receives publishing royalties from BMJ Best Practice and UpToDate; and has received research support from UCB Pharma, Thrasher Research Fund, and Citizens United for Research in Epilepsy.

Show description/summary:1) A randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study2) What's Trending: Survival and dementia in GBA-associated Parkinson disease This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the May 23, 2017 issue of Neurology. In the first segment, Dr. Matthew Barrett interviews Dr. Hubert Fernandez about his paper on deutetrabenazine for tardive dyskinesia. For our “What's Trending” feature of the week, Dr. Alberto Espay talks with Dr. Roberto Cilia about his Annals of Neurology paper on survival and dementia in GBA-associated Parkinson disease. Disclosures can be found at Neurology.org. Disclosures can be found at Neurology.org. DISCLOSURES:Dr. Barrett receives research support from Axovant Sciences, Inc., Azevan Pharmaceuticals, Merck Sharp & Dohme Corp, Virginia Center of Alzheimer´s and Related Diseases, Department of Defense Neurotoxin Exposure Treatment Parkinson's Research Program, and NIH.Dr. Fernandez serves on scientific advisory boards for Solvay Duodopa Global Study, EMD Serono Safinamide Global Study, and the Xeomin Registry (all uncompensated); has received travel or speaker honoraria from USF CME, Cleveland Clinic CME, Medical Communications Media, Health Professions Conferencing, Ipsen, Merz Pharmaceuticals, US World Meds, Prime Education Inc., Ohio State University, International Parkinson and Movement Disorders Society, Carline Communications, Medscape, Biogen GE Healthcare, Lundbeck, and Pfizer; served as Medical Editor for the Movement Disorders Society; co-owns the patent for COMPRESS; receives royalty payments from book publications with Demos Publishing, Manson Publishing, and Springer Publishing; has received research support from AbbVie, Acadia, Teva Pharmaceuticals, Biotie Therapeutics, Civitas, Kyowa Kirin International, Rhythm Pharmaceuticals, Synosia Therapeutics, Abbott, Merz Pharmaceuticals, Xeomin Registry Study, Ipsen Pharmaceuticals, Michael J. Fox Foundation, Movement Disorders Society, Huntington Study Group, Parkinson Study Group, National Parkinson Foundation, Society of Progressive Supranuclear Palsy, and NIH/NINDS.Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.Dr. Cilia receives research support from Fondazione Grigioni per il Morbo di Parkinson.

Show description/summary:1) Serum neurofilament light chain as a biomarker for mild traumatic brain injury in contact sports2) What's Trending: Biomarker validation and precision medicine in Parkinson disease.This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the May 9, 2017 issue of Neurology. In the first segment, Dr. Kristen Heinan talks with Dr. Pashtun Shahim about his paper on serum neurofilament light chain as a biomarker for mild traumatic brain injury in contact sports. In the next part of the podcast Dr. Alberto Espay focuses his discussion with Dr. David Standaert on biomarker validation and precision medicine in Parkinson disease. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.Dr. Standaert serves on scientific advisory boards for the American Parkinson Disease Association; serves on the DSMB for Shire/Biropharma; received honoraria from the Movement Disorder Society and Georgia Regents University; is Associate Editor for Movement Disorders; receives publishing royalties for Movement Disorders (McGraw-Hill Publishers, 3rd ed.); consulted for Serina Therapeutics, Kirchner Group, Teva Neuroscience, Abbvie, and the U.S. Attorney's Office; receives research support from Abbvie, Acerta Pharmaceuticals, Ceregene, Quintiles, NIH, Alabama Department of Commerce, American Parkinson Disease Association, Michael J. Fox Foundation for Parkinson Research, Bachmann-Strauss Dystonia & Parkinson Foundation, and the Dystonia Medical Research Foundation.All other participants report no disclosures.

Show description/summary:1) Reduction in Time to Treatment in Pre-hospital Telemedicine Evaluation and Thrombolysis2) What's Trending: gut microbiota regulate motor deficits and neuroinflammation in Parkinson diseaseOur podcast has changed to a two-segment format! Enjoy two in-depth interviews each week, starting with one featured article from the Neurology® family of journals followed by an interview on a trending topic or on a notable article from Neurology Today.This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the April 4, 2017 issue of Neurology. In the first segment, Dr. Andy Southerland interviews Dr. Shazam Hussain about his paper on time-to-treatment in pre-hospital telemedicine evaluation and thrombolysis. Then, for our “What's Trending” feature of the week, Dr. Alberto Espay talks with Dr. Sarkis Mazmanian about his paper on how gut microbiota regulate motor deficits and neuroinflammation in Parkinson Disease. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review.Dr. Hussain served on scientific advisory boards for pulsar neurovascular, penumbra, Inc., and Prolong Medical.Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.For full disclosures, please contact Dr. Mazmanian directly at sarkis [at] caltech.edu.

1) Practice advisory: The utility of EEG theta/beta power ration in ADHD diagnosis2) e-Pearl topic: Hemiplegic migraine3) Topic of the month: How to examine and approach movement disordersThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Adam Numis interviews Dr. David Gloss about this AAN Practice Advisory paper on the utility of EEG theta and beta power ration in attention deficit hyperactivity disorder diagnosis. Dr. Ilena George is reading our e-Pearl of the week about hemiplegic migraine. In the next part of the podcast Dr. Alberto Espay interviews Dr. Steven Frucht on the topic of “how to approach” myoclonus.DISCLOSURES: Dr. Numis served on the editorial team for the Neurology® Resident and Fellow Section. Dr. Gloss serves on the Level of evidence team for Neurology®; is an Evidence-based medicine consultant for the American Academy of Neurology; receives royalties from the publication of the book Neurology for the Specialty Boards.Dr. George serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.Dr. Frucht serves as Editor-in-Chief for the Journal of Clinical Movement Disorders; is a consultant for UCB; received speaker honoraria from Merz Pharmaceuticals, LLC and Impax; receives royalties from the publication of the book Movement Disorders Emergencies; and is employed by the American Academy of Neurology Movement Disorders Society.

1) Efficacy and safety of deflazacort versus prednisone and placebo for Duchenne muscular dystrophy2) e-Pearl topic: Alien limb phenomenon3) Topic of the month: How to examine and approach movement disordersThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Kelly Gwathmey interviews Dr. Robert Griggs about his the efficacy and safety of deflazacort versus prednisone for boys with Duchenne muscular dystrophy. Dr. Ilena George is reading our e-Pearl of the week about alien limb phenomenon. In the next part of the podcast Dr. Alberto Espay interviews Dr. Don Gilbert on the topic of tics.DISCLOSURES: Dr. Griggs serves as Correspondence Editor for Neurology®; serves as an editorial board member of NeuroTherapeutics and Current Treatment Opinions in Neurology; serves on the scientific advisory board for SAB for National Hospital Queen Square, Marathon Pharmaceuticals, PTC Therapeutics, Inc., DSMB, Taro Pharm and Sarepta Pharmaceuticals; is a consultant for Marathon, PTC Therapeutics, Sarepta, Taro Pharm and Idera Pharmaceuticals;receives royalties for data of previous studies from Taro Pharm and Marathon Pharmaceuticals; receives royalties from the publication of the books: Andreoli and Carpenter's Cecil Essentials of Medicine, Eighth Edition, Cecil Textbook of Medicine, multiple editions and Evaluation and Treatment of Myopathies; receives research support from Taro Pharma, Marathon Pharmaceuticals, Parent Project Muscular Dystrophy, Inc., Muscular Dystrophy Association, Novel Molecular Mechanisms of Neuromuscular Disease: Implications for Therapy and the NIH.Dr. George serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.Dr. Gilbert serves on the scientific advisory boards of Investigations of Neuroplasticity Mechanisms in Autism Spectrum Disorders, the Berenson-Allen Center for Noninvasive Brain Stimulation, and Beth Israel Deaconess Medical Center; received honoraria from the Tourette Association of America, the Centers for Disease Control and Prevention, and the Hong Kong Society of Child Neurology and Developmental Pediatrics; received funding for travel for educational talks to physicians and affected patients and families;receives royalties from the publication of the book Movement Disorders in Childhood, 2nd edition; receives research support from Ecopipam Pharmaceuticals, Neurocrine Pharmaceuticals, EryDel Pharmaceuticals, and NIH; and has provided expert testimony for the Health Resources and Services Administration, Department of Health and Human Services regarding Division of Vaccine Injury Compensation Programs.

1) Progression of brain atrophy in PSP and CBS over six months and one year2) What's Trending: Interview with Mike Amery about Medicare Sustainable Growth Rate repeal and the Medicare Access and CHIP Reauthorization Act 3) Topic of the month: How to examine and approach movement disordersThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. John Morgan interviews Dr. Adam Boxer about his paper about on progression of brain atrophy in progressive supranuclear palsy and corticobasal syndrome. Dr. Ted Burns is interviewing Mike Amery for our “What's Trending” feature of the week about Medicare Sustainable Growth Rate repeal and the Medicare Access and CHIP Reauthorization Act. In the next part of the podcast Dr. Alberto Espay interviews Dr. Rodger Elble on the topic of “how to approach” tremor disorders.DISCLOSURES: Dr. Morgan is a consultant for Impax, Lundbeck Inc., National Parkinson Foundation, Teva Pharmaceutical Industries Ltd., and Veloxis; serves on the speakers' bureau of Impax and Teva Pharmaceutical Industries Ltd.; received compensation for review of medical records and expert witness testimony in multiple cases of litigation involving neurologic co; receives research support from National Parkinson Foundation, Parkinson's Outcome Project Grant and the NIH.Dr. Boxer serves on the scientific advisory board for Alector, Asceneuron and Delos; received funding for travel from the International Society for CNS Clinical Trials Methodology, the Movement Disorders Society, the Association for Frontotemporal Degeneration, Fidelity Biosciences Research Institute and the Tau Consortium; is a consultant for Abbvie, Ionis, Janssen and Merck Serono; holds stock options in Alector and Delos; receives research support from Avid, Biogen Idec, BMS, C2N, Cortice, Forum, Genentech, Inc., Janssen, Pfizer Inc, Eli Lilly and Company, Roche, TauRx, The Tau Research Consortium, the Bluefield Project, Corticobasal Degeneration Solutions, the Alzheimer's Association and the NIH.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Amery is employed as Legislative Counsel for the American Academy of Neurology.Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.Dr. Elble receives research support from GlaxoSmithKline, Teva Pharmaceutical Industries Ltd., Phytopharm, Pfizer Inc, Ortho-McNeil, Spastic Paralysis Research Foundation of Kiwanis International, Illinois-Eastern Iowa District and the NIH.

1) International consensus guidance for management of myasthenia gravis2) e-Pearl topic: Progressive multifocal leukoencephalopathy3) Topic of the month: Neurology Year in Review Plenary Session at the AAN meeting on the topic of headacheThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Donald Sanders about the executive summary on the international consensus guidance for management of myasthenia gravis. Dr. Ilena George is reading our e-Pearl of the week about progressive multifocal leukoencephalopathy. Dr. Tesha Monteith interviews Dr. Richard Lipton about his Neurology Year in Review Plenary Session at the AAN meeting on the topic of headache.DISCLOSURES: Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Sanders receives royalties from the publication of the book: Single Fiber EMG; serves on the medical advisory board for Accordant Health Services; is a consultant for ArGen-X, Jacobus Pharmaceutical Co., Inc, Modus Outcomes, Momenta Pharmaceuticals, Inc. and UCB Celltech.Dr. George serves on the editorial team for the Neurology® Resident and Fellow Section.Dr. Monteith serves as an editorial advisory board member for Neurology Now and receives research support from the NIH.Dr. Lipton receives royalties for books published from Oxford University Press and Baxter Publishing; Receives honoraria for serving on the scientific advisory board for Alder, Allergan, Inc., American Headache Society, Autonomic Technologies, Avanir Pharmaceuticals, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, CoLucid, Dr. Reddys, Electrocore, Eli Lilly and Company, eNeura Therapeutics, Informa, Merck Serono, Novartis, Pfizer Inc, Teva Pharmaceutical Industries Ltd., Vedanta; is a consultant for Alder, Allergan, Inc., American Headache Society, Autonomic Technologies, Avanir Pharmaceuticals, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, CoLucid, Dr. Reddys, Electrocore, Eli Lilly and Company, eNeura Therapeutics, Informa, Merck Serono, Novartis, Pfizer Inc, Teva Pharmaceutical Industries Ltd., Vedanta; holds stock options in eNeura Pharma; receives research support from Bristol-Myers Squibb, Vedanta Research Migraine epidemiology and Progression. Boston Scientific Occipital Nerve Stimulation in Migraine, ElectroCore Vagal Nerve Stimulation for Migraine and Cluster, Novartis Sleep and Migraine, Allergan Botox in Migraine, Allergan Chronic Migraine Epidemiology and Outcome Study, S & L Marx Foundation Alzheimer's Research and the NIH.

1) Zika virus-associated Guillain-Barre Syndrome Variant in Haiti2 e-Pearl topic: Juvenile Huntington Disease3) Topic of the month: Clinical Trials Plenary Session at the AAN meeting about 5-HT6 antagonist as adjunctive therapy to cholinesterase inhibitors in patients with mild-to-moderate Alzheimer diseaseThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Stephen Donahue interviews Dr. Aaron Berkowitz about his paper on Zika virus-associated Guillain-Barre syndrome variant in Haiti. Dr. Ilena George is reading our e-Pearl of the week about juvenile Huntington disease. Dr. Alberto Espay interviews Dr. Alireza Atri about his Clinical Trials Plenary Session at the AAN meeting about 5-HT6 antagonist as adjunctive therapy to cholinesterase inhibitors in patients with mild-to-moderate Alzheimer disease.DISCLOSURES: Dr. Berkowitz receives royalties from the publication of the book: Clinical Pathophysiology Made Ridiculously Simple and the book: The Improvising Mind; received funding for travel from Stevens Institute of Technology; received speaker honorarium from Audio Digest; and received honorarium for recorded CME lecture.Dr. George serves on the editorial team for the Neurology® Resident and Fellow Section.Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.

1) Neurology® Clinical Practice: Alice in Wonderland syndrome: a systematic review2) What's Trending: Interview with Clinton Wright about his paper on leisure time physical activity and how it is associated with cognitive decline3) Topic of the month: Frontiers in Neuroscience Plenary Session at the AAN meeting about the implications for neurology and psychiatry in the treatment of cerebellar cognitive affective syndromeThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. David Lapides interviews Dr. Jan Dirk Blom about his Neurology: Clinical Practice paper on the Alice in Wonderland syndrome. Dr. Ted Burns is interviewing Dr. Clinton Wright for our “What's Trending” feature of the week about his paper on leisure time physical activity and how it is associated with cognitive decline. Dr. Alberto Espay interviews Dr. Jeremy Schmahmann about his Frontiers in Neuroscience Plenary Session at the AAN meeting about the implications for neurology and psychiatry in the treatment of cerebellar cognitive affective syndrome.DISCLOSURES: Dr. Blom receives royalties from the publication of the book Hallucinations, Research and Practice and the book A Dictionary of Hallucinations.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Wright receives royalties from UpToDate website for two chapters on vascular dementia; receives research support from American Stroke Association-Bugher Foundation Centers of Excellence project and the NIH.Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as aneditorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnologies, Michael J. Fox Foundation and the NIH.Dr. Schmahmann serves as an editorial board member of The Cerebellum and its sister journal, Cerebellum and Ataxias; serves on the scientific advisory board for Ataxion, Inc. and Atlas Ventures; Receives royalties from the publications of the books: The Cerebellum and Cognition: International Review of Neurobiology, MRI Atlas of the Human Cerebellum, Pathways of the Brain, Cerebellar Disorders in Children: Clinics in Development Medicine, and Handbook of the Cerebellum and Cerebellar Disorders; is a consultant for Takeda Pharmaceutical Company Limited; holds stock option in Ataxion, Inc. and Atlas Ventures; receives research support from Birmingham Foundation, MINDlink Foundation, Sidney R. Baer Jr., Foundation, National Ataxia Foundation, Ataxia Telangiectasia Children's Project and the NIH.NO CME WILL BE OFFERED THIS WEEK.

1) Low-cost, tablet-based option for prehospital neurologic assessment: the iTREAT Study2) What's Trending: Interview with Dafne Horovitz about her paper on cranial bone collapse in microcephalic infants prenatally exposed to Zika virus infection3) Topic of the month: Controversies in Neurology Plenary Session at the AAN meeting about the pro and con effects of cognitive enhancing activities and their effects on preventing dementiaThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Kevin Barrett interviews Dr. Andy Southerland about his paper on a low-cost, tablet-based option for prehospital neurologic assessment. Dr. Ted Burns is interviewing Dr. Dafne Horovitz for our “What's Trending” feature of the week about her paper on cranial bone collapse in microcephalic infants prenatally exposed to Zika virus infection. Dr. Alberto Espay interviews Drs. Dave Knopman and Kaycee Sink about their Controversies in Neurology Plenary Session at the AAN meeting about the pro and con effects of cognitive enhancing activities and their effects on preventing dementia.DISCLOSURES: Dr. Barrett serves as Associate Editor for Neurohospitalist; serves as an editorial board member for Neurology®; receives royalties from the publications of the books Stroke and Neurology in Practice [Edited book]; and receives research support from the NIH.Dr. Southerland serves as Podcast Deputy Editor for Neurology®; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Horovitz serves as Associate Editor for Journal of Community Genetics; received speaker honoraria from Biomarin Pharmaceutical, Genzyme-Sanofi, Shire Pharmaceuticals, Inc. and Alexion Pharmaceuticals, Inc.; received funding for travel to medical meeting from Genzyme-Sanofi and Shire Pharmaceuticals, Inc.Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.Dr. Knopman serves on the scientific advisory board for Consultant Bluefield project, Lundbeck Pharmaceuticals Inc., DIAN study DSMB; served as Associate Editor for Neurology® until October 2015; receives research support from the NIH, Mayo Alzheimer's Disease Research Center, Mayo Alzheimer Disease Patient Registry, ARIC Dementia Study and Chronic Kidney Disease and Cognitive functioning; received funding for travel to two lectures Alzheimer Conference, Seoul Korea and Behavioral Neurology Conference, Hyderabad, India.Dr. Sink served on the data safety monitoring board for two NIH funded clinical trials; initiated grants from the Alzheimer's Association and the Donald W. Reynolds Foundation as an investigator; received research support from the NIH.

1) Quality improvement in neurology: Parkinson disease update quality measurement set2) What's Trending: Amyloid pathology and axonal injury after brain trauma 3) Topic of the month: George C. Cotzias Lecture at the AAN Meeting on antibody mediated disorders of the synapseThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Binit Shah interviews Drs. Janis Miyasaki and Stewart Factor about the AAN paper on new quality measures developed to improve outcomes for patients with Parkinson disease. Dr. Ted Burns is interviewing Dr. Ansgar Furst for our “What's Trending” feature of the week about his editorial on incidental findings for what's to come in amyloid plaques in traumatic brain injury. Dr. Alberto Espay interviews Dr. Josep Dalmau about his George C. Cotzias Lecture at the AAN Meeting on the topic of antibody mediated disorders of the synapse.DISCLOSURES: Dr. Miyasaki received honoraria and funding for travel from Teva Pharmaceutical Industries Ltd.; received funding for travel from Merz Pharmaceuticals, LLC; received travel honoraria from The International Parkinson Disease and Movement Disorders Society; is a consultant for Merz Pharmaceuticals, LLC; receives royalties from the publication of the book “Psychogenic Movement Disorders;” receives research support from PCORI: 2015-2018 and Parkinson Alberta.Dr. Factor served as an editorial board member of Neurotherapeutics; serves on the data safety monitoring board for Lundbeck, Inc; is a consultant for UCB; is a consultant and video reviewer for clinical trials for Avanir, Neurocrine and Auspex/Teva Pharmaceutical Industries Ltd.; receives royalties from the publications of the books “Parkinson's disease diagnosis and clinical management” and “Drug induced movement disorders;” gave expert testimony in Kmart trial (2014-2016); receives research support from Ceregene, Cynapsus, Sangamo, Teva Pharmaceutical Industries Ltd., Ipsen Pharmaceuticals, Inc., USWorldMeds, Allergen, Inc., Medtronics, Inc., Auspex, Genzyme Corporation, Michael J. Fox Foundation and the NIH.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.Dr. Dalmau serves as Editor of Neurology®: Neuroimmunology & Neuroinfammation; serves as an Editorial board member of Neurology® and UpToDate; receives royalties from patents for the use of Ma2 and NMDAR as autoantibody tests; is a consult for Advance Medical, receives research support from Euroimmun and the NIH; receives revenue from Euroimmun for the following tests: NMDA receptor autoantibody test, GABA(B)R autoantibody test, GABA(A)R autoantibody test, DPPX autoantibody test and Iglon5 autoantibody test.

1) Neurology® Genetics: Clinical and genetic features of cervical dystonia in a large multi-center cohort 2) What's Trending: Amyloid pathology and axonal injury after brain trauma 3) Topic of the month: Abstract presentation at the AAN meeting on the spectrum of multiple sclerosis misdiagnosis in the era of McDonald criteriaThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Michelle Fullard interviews Dr. Mark LeDoux about his Neurology: Genetics paper on the clinical and genetic features of cervical dystonia. Dr. Ted Burns is interviewing Dr. Dave Sharp for our “What's Trending” feature of the week about his paper on amyloid pathology and axonal injury after brain trauma. Dr. Andy Southerland interviews Dr. Andy Solomon about his abstract presentation at the AAN meeting on the spectrum of multiple sclerosis misdiagnosis in the era of McDonald criteria.DISCLOSURES: Dr. LeDoux serves on the scientific advisory boards of Spastic Paraplegia Foundation; serves as Chairman on the board of medical advisors of the National Spasmodic Torticollis Association; serves as an editorial board member of Parkinsonism and Related Disorders, Tremor and other hyperkinetic movement disorders, PLOS ONE and Neurology®; is a consultant for Azilect Advisory Board, Mayo Clinic, Teva Pharmaceutical Industries Ltd., Lundbeck Inc.; serves on the speakers' bureau of Teva Pharmaceutical Industries Ltd. and Lundbeck Inc.; receives funding for travel from Teva Pharmaceutical Industries Ltd. and Lundbeck Inc.; receives royalties from the publication of the books “Animal models of movement disorders” and “Movement disorders: Genetics and models;” receives research support from Benign Essential Blepharospasm Research FDN, CHDI, Enroll HD, Omeros, Phase 2, Auspex, US WorldMeds, Mysticol, Protocol, Accorda and the NIH.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Sharp receives research support from UK Medical Research Council, European Union, Wellcome Trust, Rosetrees Trust, Action Medical Research, Public engagement grant from The Physiological Society, The Royal Society Summer Science Exhibition and the NIH (UK).Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review.Dr. Solomon received research support from the Portland Veterans Affairs Medical Center Fellowship in Multiple Sclerosis and Neuroimmunology and Partners Multiple Sclerosis Fellowship Award.NO CME WILL BE OFFERED THIS WEEK.

1) The association between hospitalization and care after transient ischemic attack or minor stroke2) e-Pearl topic: Neuroretinitis3) Topic of the month: Migraine awareness seriesThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Dr. Moira Kapral about her paper on the association between hospitalization and care after transient ischemic attack or minor stroke. Dr. Sarah Wesley is reading our e-Pearl of the week about neuroretinitis. Dr. Tesha Monteith interviews Dr. Stephen Silberstein about the topic of migraine clinical trials: A drug therapy and neuromodulation update. DISCLOSURES: Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke viamobile telemedicine;” and gave legal expert review.Dr. Kapral serves as Guest Editor for Cardiovascular Quality and Outcomes; serves as an editorial board member of Circulation; receives research support from the Heart and Stroke Foundation of Canada.Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section.Dr. Monteith serves as an editorial advisory board member for Neurology Now and receives research support from the NIH.Dr. Silberstein serves as an editorial board member of Cephalalgia, Current Pain and Headache Reports, CNS Drugs, Topics in Pain Management and Neurology®; serves on the scientific advisory board for Alder, Allergan, Inc., Amgen, Avanir, eNeura, ElectroCore Medical, Medscape, Medtronic, Inc., Mitsubishi Tanabe Pharma Corporation, Neuralieve, NINDS, Pfizer Inc, Supernus and Teva Pharmaceutical Industries Ltd.; is a consultant for Allergan, Inc., Amgen, eNeura, ElectroCore Medical, Mitsubishi Tanabe, Medtronic, Inc., Neuralieve, Pfizer, Inc, Supernus and Teva Pharmaceutical Industries Ltd.; receives research support from American Headache Society®, International Headache Society and the NIH.

1) Transient ischemic attack service provision: A review of available service models2) What's Trending: Mediterranean diet and brain structure in a multiethnic elderly cohort3) Topic of the month: Pediatric multiple sclerosis This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Bryan Eckerle interviews Dr. Anna Ranta about her paper on transient ischemic attacks as predictors of high risk for subsequent strokes. Dr. Ted Burns is interviewing Dr. Yian Gu for our “What's Trending” feature of the week about his paper on the Mediterranean diet and brain structure in a multiethnic elderly cohort. In the next part of the podcast Dr. Nick Brenton interviews Dr. Daniela Pohl about the topic of disease-modifying therapy management in pediatric multiple sclerosis. DISCLOSURES: Dr. Ranta receives research support from the New Zealand Health Research Council.Dr. Ted Burns serves as Podcast Editor for Neurology; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Pohl received funding for travel from Teva Pharmaceutical Industries Ltd., Bayer Schering Pharma, ENS, Merck Serono, Consortium of Multiple Sclerosis Center, LACTRIMS and National Multiple Sclerosis Society; received speaker honoraria from Teva Pharmaceutical Industries Ltd., Bayer Schering Pharma, Merck Serono and Consortium of Multiple Sclerosis Center; serves on the scientific advisory board for Biogen Idec and Merck Serono.

1) Stroke risk stratification in acute dizziness presentations and 2) Topic of the month: Neuromyelitis optica. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Dr. Kevin Kerber about his paper on stroke risk stratification in acute dizziness presentations. Dr. Sarah Wesley is reading our e-Pearl of the week about focal cortical dysplasia. In the next part of the podcast Dr. Stacey Clardy interviews Dr. Jacqueline Palace about the topic of aquaporin-4 molecular mimicry/pathogenesis/research developments. The participants had nothing to disclose except Drs. Southerland, Kerber, Wesley, Clardy and Palace.Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc.Dr. Kerber received funding for travel from Elsevier Inc. and the American Academy of Neurology; receives royalties from the publication of the book Clinical Neurophysiology of the Vestibular System, 4th edition; is a consultant for the American Academy of Neurology, University of California San Francisco (including work on a project funded by AstraZeneca), and Best Doctors, Inc.; receives research support from the NIH; received speaker honoraria from American Academy of Neurology and University of California San Francisco and loan repayment award from the NIH; reviewed legal records of Phil Pearsons, MD, JD and National Medical Consultants.Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section.Dr. Clardy receives research support from the Western Institute for Biomedical Research.Dr. Palace serves as on the scientific advisory board for Merck Serono, Bayer Schering Pharma, Biogen Idec, Teva Pharmaceutical Industries Ltd., Novartis Pharmaceuticals UK Ltd., Sanofi-aventis, Alexion; received support for attending ECTRIMS Merck Serono Novartis and Biogen Idec Talks at scientific meetings (majority have CME) Bayer Schering Pharma, Biogen Idec, Merck Serono, Medimmune; is a consultant for Ono Pharmaceuticals Ltd., Chugai Pharma Ltd., CI Consulting, Biogen Idec, GlaxoSmithKline, Alexion; serves on the speakers' bureau of Teva The CMSC, U. S.; receives research support from Bayer Schering Pharma, Merck Serono, Novartis Teva Pharmaceutical Industries Ltd., MS Society UK, Guthy Jackson Foundation and Department of Health Risk Sharing Scheme, Clinical Coordinator since 2002 Department of Health funding for a neuromyelitis optica service and a congenital myasthenia service; receives revenue from a patent from ISIS innovation Limited, a wholly-owned subsidiary of the University of Oxford, has filed a patent application (WO2013/117930 A2) to protect for the use of metabolomics as a method to diagnose and stage disease in multiple sclerosis.

1) Neurology® Genetics: Phenotypic and molecular analyses of primary lateral sclerosis and 2) Topic of the month: Neurology Today: Recent Publications. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Elliot Dimberg interviews Dr. Hitoshi Mitsumoto about his Neurology: Genetics paper on the phenotypic and molecular analyses of primary lateral sclerosis. Dr. Adam Numis is reading our e-Pearl of the week about cerebral amyloid angiopathy-related inflammation. In the next part of the podcast Dr. Ted Burns interviews Dr. Steve Ringel about a Neurology Today story on the topic of systemic exertion intolerance disease. The participants had nothing to disclose except Drs. Dimberg, Mitsumoto, Numis, Burns and Ringel.Dr. Dimberg serves as an editorial board member of Nerve and Muscle Junction Podcast.Dr. Mitsumoto is a consultant for Biogen Idec; receives research support from Avanir Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Sanofi-aventis, Biogen Idec and the NIH.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Ringel serves as editor of Neurology Today.NO CME WILL BE OFFERED THIS WEEK.

1) Migraine and risk of stroke in older adults and 2) Topic of the month: Plenary sessions AAN Meeting April 2015. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Dr. Teshamae Monteith about her paper on migraine and risk of stroke in older adults. Dr. Adam Numis is reading our e-Pearl of the week about neurosyphilis. In the next part of the podcast Dr. Alberto Espay interviews Dr. Keith Josephs about his Frontiers in Neuroscience Lecture at the AAN Meeting about the topic of antemortem signatures of neurodegenerative proteinopathies. The participants had nothing to disclose except Drs. Southerland, Monteith, Numis, Espay and Josephs.Dr. Southerland serves as Podcast Deputy Editor for Neurology®; serves as Clinical Research Advisor for Totier Technologies, Inc.Dr. Monteith serves as an editorial advisory board member for Neurology Now; and receives research support from the NIH.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH.

1) Opioids for chronic non-cancer pain and 2) Topic of the month: Plenary sessions AAN Meeting April 2015. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Drs. Stephen Nadeau and Gary Franklin about their papers on opioids for chronic non-cancer pain and the policy behind prescribing them. Dr. Adam Numis is reading our e-Pearl of the week about vaccinations and seizures. In the next part of the podcast Dr. Alberto Espay interviews Dr. Virginia Lee about her Frontiers in Neuroscience Lecture at the AAN Meeting about the topic of transmission of alpha-Synuclein in Parkinson disease: Pathogenesis and implications for therapy. The participants had nothing to disclose except Drs. Burns, Nadeau, Franklin, Numis, Espay and Lee.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc.Dr. Nadeau served on the DSMB for the National Institute of Neurological Disorders and Stroke and National Institute of Child Health and Human Development funded Interdisciplinary Comprehensive Arm Rehab Evaluation, DSMB ; served as an Associate Editor of the Journal of the International Neuropsychological Society; received honoraria and funding for travel for an International Neuropsychological Society meeting; received funding for travel for an American Neuropsychiatric Association meeting; receives royalties from the publication of the book The Neural Architecture of Grammar ; and receives research support from a VA Rehabilitation R&D Grant and University of Florida McKnight Brain Institute Brain and Spinal Cord Injury Research Trust Fund Grant.Dr. Franklin serves as an editorial board member of Neurology® Levels of Evidence Team and Neuroepidemiology; is a consultant for the California State Compensation Insurance Fund and receives research support from the Centers for Disease Control and Prevention (CDC).Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH.Dr. Lee serves as an editorial board member of Laboratory Investigation, Neurorehabilitation and Neural Repair, NeuroSignals, Neuron, Experimental Neurology, Science Magazine; receives research support from Ware Benaroya and the NIH; receives revenue for the following patent: "Compositions and Methods for Producing and Using Homogeneous Neuronal Cell Transplants" Penn G1120, Patent # 5,792,900.

1) CIDP diagnostic pit-falls and perception of treatment benefits and 2) Topic of the month: Plenary sessions AAN Meeting April 2015. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Michelle Mauermann interviews Dr. Jeffrey Allen about his paper on chronic inflammatory demyelinating polyneuropathy diagnostic pit-falls and perception of treatment benefits. Dr. Adam Numis is reading our e-Pearl of the week about exam findings in hemifacial spasms. In the next part of the podcast Dr. Alberto Espay interviews Dr. Howard Weiner about his Frontiers in Neuroscience Lecture at the AAN Meeting about the topic of immune mechanisms in neurologic diseases. The participants had nothing to disclose except Drs. Mauermann, Allen, Numis, Espay and Weiner.Dr. Mauermann receives research support from ISIS Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc. and the NIH.Dr. Allen is a consultant for AxelaCare and CSL Behring.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH.Dr. Weiner is a consultant for Biogen Idec, Novartis, Merck Serono, Sanofi-aventis, Teva Pharmaceutical Industries Ltd. and Therapix Biosciences Ltd.; served on the advisory board for The Guthy Jackson Charitable Foundation, Teva Pharmaceutical Industries Ltd., Biogen Idec, Novartis, Sanofi-aventis; receives research support from EMD, Merck Serono, National Multiple Sclerosis Society, and the NIH.

1) Aerobic training and post-exercise protein in facioscapulohumeral muscular dystrophy and 2) Topic of the month: Plenary sessions AAN Meeting April 2015. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Erik Ensrud interviews Dr. Grete Andersen about her paper on aerobic training and post-exercise protein in facioscapulohumeral muscular dystrophy. Dr. Adam Numis is reading our e-Pearl of the week about non-invasive imaging of arterial dissection with MRI. In the next part of the podcast Dr. Alberto Espay interviews Dr. Stefan Pulst about his George C. Cotzias Lecture at the AAN Meeting about the topic of degenerative ataxias: From genes to therapies. The participants had nothing to disclose except Drs. Ensrud, Numis, Espay and Pulst.Dr. Ensrud serves on the data safety monitoring board for phase II trial of methotrexate in myastenia gravis; is a consultant for Skulpt/Convergence Medical Devices and FDA; received honoraria and funding for travel from Osler Institute; received funding for travel from American Association of Physical Medicine and Rehabilitation; and received honoraria from American Association of Neuromuscular and Electrodiagnostic Medicine.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH.Dr. Pulst serves as Editor-in-Chief of Current Genomics; serves as Editor of Neurology® Genetics; serves as an editorial board member of Journal of Cerebellum, NeuroMolecular Medicine, Continuum, Experimental Neurology, Neurogenetics, and Nature Clinical Practice Neurology; is author on patents re: Nucleic acids encoding ataxin-2 binding proteins; Nucleic acid encoding Schwannomin-binding-proteins and products related thereto; Transgenic mouse expressing a polynucleotide encoding a human ataxin-2 polypeptide; Methods of detecting spinocerebellar ataxia-2 nucleic acids; Nucleic acid encoding spinocerebellar ataxia-2 and products related thereto; Schwannomin-binding-proteins; and Compositions and methods for spinocerebellar ataxia; receives royalties from the publications of the books The Ataxias, Genetics in Neurology, Genetics of Movement Disorders, Neurogenetics, and Molecular Genetic Testing in Neurology, 2nd–5th ed.; serves on the speakers' bureau for Athena Diagnostics; receives research support from the NIH and the National Ataxia Foundation; receives license fee payments from Cedars-Sinai Medical Center; and has provided expert testimony in a medico-legal case.

1) Evaluation, diagnosis and management of facioscapulohumeral muscular dystrophy and 2) Topic of the month: Plenary sessions AAN Meeting April 2015. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Rabi Tawil about his paper on the evaluation, diagnosis and management of facioscapulohumeral muscular dystrophy. Dr. Sarah Wesley is reading our e-Pearl of the week about vertical nystagmus. In the next part of the podcast Dr. Alberto Espay interviews Dr. Helen Mayberg about her Robert Wartenberg Lecture at the AAN Meeting on the topic of what deep brain stimulation has taught us about the neurology of depression. The participants had nothing to disclose except Drs. Burns, Tawil, Wesley and Espay.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc.Dr. Tawil serves as an editorial board member of Journal of Neuromuscular Diseases; serves on the safety monitoring board of Novartis; receives royalties from the publication of the books Neuromuscular Disorders (Rabi N. Tawil & Shannon Venance, Editors) and Neurology in Practice Series; receives research support from the NIH and Spinal Muscular Atrophy Foundation.Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH.

1) Paraneoplastic neurologic disorders in small cell lung carcinoma and 2) Topic of the month: Plenary sessions AAN Meeting April 2015. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Elliot Dimberg interviews Dr. Paul Gozzard about his paper on paraneoplastic neurologic disorders in small cell lung carcinoma. Dr. Sarah Wesley is reading our e-Pearl of the week about Balint Syndrome. In the next part of the podcast Dr. Alberto Espay interviews Dr. Lloyd Kasper about his Hot Topic Lecture at the AAN Meeting on the topic of digesting the gut microbiome: role in CNS demyelinating disease. The participants had nothing to disclose except Drs. Dimberg, Wesley and Espay.Dr. Dimberg serves as an editorial board member of Nerve and Muscle Junction Podcast.Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH.

1) Early EEG contributing to multimodal outcome prediction of postanoxic coma and 2) Topic of the month: Plenary sessions AAN Meeting April 2015. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Schomer interviews Dr. Jeannette Hofmeijer about her paper on early EEG contributing to multimodal outcome prediction of postanoxic coma. Dr. Sarah Wesley is reading our e-Pearl of the week about Susac syndrome. In the next part of the podcast Dr. Alberto Espay interviews Dr. Daniel Lowenstein about his H. Houston Merritt Lecture at the AAN Meeting on the topic of advances in the treatments for epilepsy. The participants had nothing to disclose except Drs. Wesley, Espay and Lowenstein.Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH.Dr. Lowenstein receives research support from the NIH.

1) Switching from natalizumab to fingolimod in patients with remitting-relapsing multiple sclerosis and 2) Topic of the month: Plenary sessions AAN Meeting April 2015. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mark Keegan interviews Dr. Ludwig Kappos about his paper on switching from natalizumab to fingolimod in patients with remitting-relapsing multiple sclerosis. Dr. Sarah Wesley is reading our e-Pearl of the week about dopamine-responsive dystonia. In the next part of the podcast Dr. Alberto Espay interviews Dr. Timothy Pedley about his Presidential Lecture at the AAN Meeting about the topics of neurologists' burnout, cost and quality of healthcare, value of neurology to congress and payers along with maintenance of certification. The participants had nothing to disclose except Drs. Keegan, Kappos, Wesley, Espay and Pedley.Dr. Keegan serves as Chief Editor of eMedicine; serves as an editorial board member of Multiple Sclerosis and Related Disorders; is a consultant for Novartis, Bristol-Meyers Squibb, Bionest Partners and receives research support from Terumo BCT and Caridian BCT.Dr. Kappos serves as an editorial board member of Multiple Sclerosis Journal, Multiple Sclerosis and Related Disorders and Journal of Neurology; receives research support from Actelion Pharmaceuticals Ltd, Addex, Bayer Schering Pharma, Biogen Idec, Biotica, CSL Behring, Genzyme Corporation, Eli Lilly and Company, Merck Serono, Mitsubishi, Novartis, Ono Pharma, Pfizer Inc, Receptos, Roche, Sanofi-aventis, Santhera, Siemens, Teva Pharmaceutical Industries Ltd., UCB, Xenoport, Swiss National Research Foundation and the European Union and The Swiss MS Society; honoraria and other payments for all these activities have been exclusively used for funding of research of his department.Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH.Dr. Pedley serves as an editorial board member of Journal of Clinical Neurophysiology and Nature Reviews Neurology and as Editor-in-Chief (Neurology) for UpToDate; serves as President for the American Academy of Neurology; receives royalties form the publication of the books Current Practice of Clinical Electroencephalography, Epilepsy: A comprehensive Textbook and Merritt's Neurology.

1) Olfactory dysfunction predicting early transition to Lewy body disease in idiopathic RBD and 2) Topic of the month: Autoimmune and paraneoplastic encephalitis. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Binit Shah interviews Dr. Werner Poewe about his paper on olfactory dysfunction predicting early transition to Lewy body disease in idiopathic RBD. Dr. Adam Numis is reading our e-Pearl of the week about Fragile X tremor ataxia syndrome. In the next part of the podcast Dr. Stacy Clardy interviews Dr. Josep Dalmau about other recently described antibodies associated with autoimmune encephalitis. The participants had nothing to disclose except Drs. Poewe, Numis and Dalmau.Dr. Poewe has received consultancy and lecture fees from Abbott, AstraZeneca, Teva Pharmaceutical Industries Ltd, Novartis, GlaxoSmithKline, Boehringer Ingelheim, UCB, Orion Pharma Ltd., and Merck Serono in relation to clinical drug development programs for Parkinson disease; has received research support from the Michael J. Fox Foundation; receives royalties from the publications of the books: Therapeutics of Parkinson's disease and other movement disorders, Non-motor symptoms of Parkinson's disease and Parkinson-syndrome und andere Bewegungsstorungen.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Dalmau serves as an editorial board member of Neurology® and UptoDate; serves as Editor-in-Chief of Neurology® Neuroimmunology and Neuroimflammation; is a consultant for Advance Medical; receives royalties for the following patents: Patent Ma2 autoantibody test, Patent NMDAR autoantibody test, patent application for the use of GABA(B) receptor, DPPX and IgLON5 autoantibody tests; received license fee payments for DPPX and IgLON5 autoantibody tests from Euroimmun; receives research support from Euroimmun, ISCIII, and the NIH.

1) Imaging prodromal Parkinson disease and 2) Topic of the month: Movement disorder emergencies. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Alberto Espay interviews Dr. Danna Jennings about her paper on imaging prodromal Parkinson disease. Dr. Adam Numis is reading our e-Pearl of the week about distal hereditary neuropathies. In the next part of the podcast Dr. David Taplinger interviews Dr. Steven Frucht about the movement disorder emergency: serotonin syndrome. The participants had nothing to disclose except Drs. Espay, Jennings, Numis and Frucht.Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of Novartis, UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH.Dr. Jennings received speaker honoraria from Novartis; serves on the speaker board of UCB; receives research funding from Michael J. Fox Foundation, FORUM Pharmaceuticals, Concert Pharmaceuticals, Inc.; Omeros, Amgen, Abbvie, Merck Serono, Eli Lilly and Company, Avid Radiopharmaceuticals, Inc.; Navidea Biopharmaceuticals, Inc.; Eisai Inc., TauRx Therapeutics Ltd and Biogen Idec.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Frucht is a consultant for Merz Pharmaceuticals, LLC and Impax Pharmaceuticals and receives royalties from the publication of the book Movement Disorders Emergencies.

1) Evaluation and construction of diagnostic criteria for inclusion body myositis and 2) Topic of the month: Plenary sessions AAN Meeting April 2014. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Steven A. Greenberg about his paper on evaluation and construction of diagnostic criteria for inclusion body myositis. Dr. James Addington is reading our e-Pearl of the week about Rapid-Onset Dystonia Parkinsonism. In the next part of the podcast Dr. Alberto Espay continues his interview with Dr. Jon Stone including questions about his Contemporary Clinical Issues Lecture about functional (psychogenic) disorders in neurology from the audience at Interview Central and his responses. The participants had nothing to disclose except Drs. Burns, Greenberg, Addington, Espay and Stone.Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc.Dr. Greenberg is a consultant for MedImmune, aTyr Pharma; receives publishing royalties from the publication of the book EMG Pearls; receives license fee payments from Composition and Methods for Diagnosing and Assessing Inflammatory Myopathies, MedImmune; receives revenue for patents for composition and methods for diagnosing and assessing inflammatory myopathies, detecting inclusion body myositis; receives research support from MedImmune, Novartis and the NIH; serves on the scientific advisory board for MedImmune; received funding for travel from Biogen Idec and Genzyme Corporation.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of Novartis, UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH.Dr. Stone received speaker honoraria from the Movement Disorders Society, British Medical Association, American Academy of Neurology Royal College of Psychiatrists, UCB Pharma, Novartis, Tribunals Judiciary (UK); receives research support from the National Research Strategy Career Fellow with NHS Scotland Research; receives publishing royalties from UptoDate 2014; runs a free self-help website for patients with functional disorders www.neurosymptoms.org; carries out regular expert witness work in relation to personal injury and medical negligence.

1) Traumatic brain injury and risk of dementia in older veterans and 2) Topic of the month: Plenary sessions AAN Meeting April 2014. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Farrah Mateen interviews Dr. Deborah Barnes about her paper on traumatic brain injury and risk of dementia in older veterans. Dr. James Addington is reading our e-Pearl of the week about chronic traumatic encephalopathy. In the next part of the podcast Dr. Alberto Espay interviews Dr. Jon Stone about his Contemporary Clinical Issues Lecture at the AAN Meeting about functional (psychogenic) disorders in neurology. The participants had nothing to disclose except Drs. Mateen, Barnes, Addington, Espay and Stone.Dr. Mateen received funding support from the Canadian Institute of Health Research.Dr. Barnes receives research support from UCB, Department of Defense, Department of Veterans Affairs, NARSAD (Brain & Behavior Research Foundation), S.D. Bechtel Jr. Foundation, philanthrophic support via Osher Center for Integrative Medicine, University of California, San Francisco, patient centered outcomes research institute and the NIH.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of Novartis, UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH.Dr. Stone received speaker honoraria from the Movement Disorders Society, British Medical Association, American Academy of Neurology Royal College of Psychiatrists, UCB Pharma, Novartis, Tribunals Judiciary (UK); receives research support from the National Research Strategy Career Fellow with NHS Scotland Research; receives publishing royalties from UptoDate 2014; runs a free self-help website for patients with functional disorders www.neurosymptoms.org; carries out regular expert witness work in relation to personal injury and medical negligence.

1) Defining the clinical course of multiple sclerosis: The 2013 revisions and 2) Topic of the month: Plenary sessions AAN Meeting April 2014. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mark Keegan interviews Dr. Fred Lublin about his paper on defining the clinical course of multiple sclerosis: The 2013 revisions. Dr. James Addington is reading our e-Pearl of the week about familial fatal insomnia. In the next part of the podcast Dr. Alberto Espay interviews Dr. David Eidelberg about his Hot Topics Lecture at the AAN Meeting about functional connectivity and functional imaging in movement disorders. The participants had nothing to disclose except Drs. Keegan, Lublin, Addington, Espay and Eidelberg.Dr. Keegan serves as Chief Editor of eMedicine and receives research support from Terumo BCT.Dr. Lublin serves as co-Chief Editor of Multiple Sclerosis and Related Disorders; serves on the scientific advisory boards and as a consultant for Bayer Schering Pharma, Biogen Idec, Merck Serono, Novartis, Teva Pharmaceutical Industries Ltd., Actelion Pharmaceuticals Ltd, Sanofi-aventis, Acorda Therapeutics Inc, Questcor Pharmaceuticals, Roche, Genentech, Inc., Celgene, Johnson & Johnson, Revalesio Corporation, Coronado Bioscience, Genzyme Corporation, MedImmune, Bristol-Myers Squibb, XenoPort, Inc., Receptos Inc, Forward Pharma, to- BBB technologies; receives research support from Biogen Idec, Teva Pharmaceutical Industries Ltd., Acorda Therapeutics Inc, Novartis, Genzyme Corporation, Sanofi-aventis, Celgene, National Multiple Sclerosis Society and the NIH; holds financial interests/stock options in Cognition Pharmaceuticals. Inc. and may discuss unapproved agents that are in the MS developmental pipeline with any recommendations on their use.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of Novartis, UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH.Dr. Eidelberg serves as an Associate Editor of Journal of Neuroscience; serves as an editorial board member of Journal of Nuclear Medicine, Current Opinion in Neurology, Annals of Neurology and NeuroImage; serves on the scientific advisory board for the Michael J. Fox Foundation, ; co-inventor of United States Patent No. 5, 632,276 and No. 5,873,823 without financial gain; receives research support from the Michael J. Fox Foundation and the NIH.

1) Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease and 2) Topic of the month: Plenary sessions AAN Meeting April 2014. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. John Mytinger interviews Dr. Russell Dale about his paper on utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Dr. James Addington is reading our e-Pearl of the week about pseudo-internuclear ophthalmoplegia. In the next part of the podcast Dr. Alberto Espay interviews Dr. David Holtzman about his Robert Wartenberg Lecture at the AAN Meeting about Alzheimer's disease in 2014: Mapping a road forward. The participants had nothing to disclose except Drs. Dale, Addington, Espay and Holtzman.Dr. Dale serves on the scientific advisory board for Queensland Children's Medical Institute; serves as an editorial advisory board member of Multiple Sclerosis and Related Disorders Journal; received honoraria for lecturing from Biogen Idec; receives research support from the National Health and Medical Research Council. Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of Novartis, UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH.Dr. Holtzman serves as an Associate Editor of Annuals of Neurology; serves as an editorial board member of Neurobiology of Disease, Experimental Neurology, Molecular Neurodegeneration, Science Translational Medicine and Journal of Experimental Medicine; co-founder of C2N Diagnostic LLC; is a consultant for AstraZeneca, Genentech, Inc., Bristol-Myers Squibb and Forum Pharmaceuticals; receives research support AstraZeneca, Eli Lilly and Company, Biogen Idec, C2N Diagnostic LLC, Cure Alzheimer's Disease, Tau Consortium, Ellison Medical Foundation and the NIH.

1) Long-term safety and effectiveness of natalizumab for re-dosing and treatment of multiple sclerosis and 2) Topic of the month: Plenary sessions AAN Meeting April 2014. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ruth Ann Marrie interviews Dr. Paul O'Connor about his paper on long-term safety and effectiveness of natalizumab for re-dosing and treatment of multiple sclerosis. Dr. James Addington is reading our e-Pearl of the week about inclusion body myositis. In the next part of the podcast Dr. Alberto Espay interviews Dr. James Bernat about his Presidential Lecture at the AAN Meeting about challenges to ethics and professionalism facing the contemporary neurologist. The participants had nothing to disclose except Drs. Marrie, O'Connor, Addington, Espay and Bernat.Dr. Marrie serves on the editorial board for Neurology® and Multiple Sclerosis Journal; receives research support from Sanofi-aventis, Canadian Institutes of Health Research, Public Health Agency of Canada, Multiple Sclerosis Society of Canada, National Multiple Sclerosis Society, Multiple Sclerosis Scientific Foundation and Consortium of Multiple Sclerosis Centers.Dr. O'Connor served on the editorial advisory board of the MS Journal; serves on the scientific advisory board for Novartis, Sanofi-aventis, Bravo Pharmaceuticals, Genentech, Inc., Roche and Actelion Pharmaceuticals Ltd; is a consultant for Biogen Idec, Teva Pharmaceutical Industries Ltd., Sanofi-aventis and Novartis; received funding for travel to advisory board meeting in Toronto; receives research support from Novartis, Sanofi-aventis, Roche, Biogen Idec and as National Scientific and Clinical Advisor to the MS Society of Canada. Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of Novartis, UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH.Dr. Bernat serves as an unpaid editorial board member of Neurocritical Care, Neurology Today, and Multiple Sclerosis and Related Diseases; a paid editorial board member of The Physician's Index for Ethics and Medicine; and receives royalties from the publication of the books Ethical Issues in Neurology, 3rd ed, Palliative Care in Neurology, and Ethical and Legal Issues in Neurology.

1) Factors associated with recovery from acute optic neuritis in multiple sclerosis and 2) Topic of the month: Neuro-infectious diseases. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mark Keegan interviews Dr. Tanuja Chitnis about her paper on factors associated with recovery from acute optic neuritis in multiple sclerosis. Dr. Adam Numis is reading our e-Pearl of the week about tanycytic ependymal tumors. In the next part of the podcast Dr. Chenjie Xia interviews Dr. Karen Roos about neurology and infectious diseases: Bacterial meningoencephalitides. The participants had nothing to disclose except Drs. Jen, Tedeschi, Numis and Roos.Dr. Keegan serves as Chief Editor of eMedicine and receives research support from Terumo BCT.Dr. Chitnis is a consultant for Biogen Idec, Teva Pharmaceutical Industries Ltd., Novartis, Sanofi-aventis; receives research support from Merck Serono and Novartis in the form of Independent Investigator Awards, National Multiple Sclerosis Society. the Peabody Foundation and the Guthy-Jackson Charitable Foundation.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Roos receives royalties for five published books.

1) Effects of cannabis on cognition in patients with multiple sclerosis and 2) Topic of the month: Critical care neurology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Alex Menze interviews Dr. Anthony Feinstein about his paper on the effects of cannabis on cognition in patients with multiple sclerosis. Dr. James Addington is reading our e-Pearl of the week about spinal dural arteriovenous fistula. In the next part of the podcast Dr. Mike Brogan interviews Dr. Claude Hemphill about the management of intracranial hypertension. The participants had nothing to disclose except Drs. Feinstein, Addington and Hemphill.Dr. Feinstein serves as an editorial board member of Multiple Sclerosis and African Journal of Psychiatry; receives royalties from the publication of the book The Clinical Neuropsychiatry of Multiple Sclerosis; performs neuropsychiatric evaluation, cognitive testing, brain imaging in neuropsychiatry clinical practice; receives research support from Biogen Idec, Canadian Institute of Health Research, Multiple Sclerosis Society of Canada and University of Toronto; received honoraria for lectures from Merck Serono, Novartis and Teva Pharmaceutical Industries Ltd.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Hemphill serves as an editorial board member of Neurocritical Care; holds stock options for serving on the scientific advisory board for Ornim Medical; receives research support from Cerebrotech Medical; funding as PI for hub site for Neurological Emergencies Treatment Trials Network; received a one-time speaking honorarium from Besins Critical Care, LLC and honoraria from Edge Therapeutics, Inc. for consulting; gave expert witness review and testimony on various cases related to stroke and neurocritical care.

1) Influence of age at surgical menopause influences cognitive decline and Alzheimer's pathology in older women and 2) Topic of the month: Parkinson's and parkinsonism disorders. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Burns interviews Drs. Riley Bove and Philip De Jager about their paper on the influence of age at surgical menopause influences cognitive decline and Alzheimer's pathology in older women. Dr. Adam Numis is reading our e-Pearl of the week about parechovirus and neurologic disease. In the next part of the podcast Dr. Binit Shah interviews Dr. Anthony Lang about non-neurodegenerative causes of parkinsonism - drug-induced; structural: NPH, stroke, tumor; psychogenic. The participants had nothing to disclose except Drs. Burns, Bove, De Jager, Numis and Lang.Dr. Jeff Burns serves on the editorial board for Journal of Alzheimer's Disease; receives royalties for the publications of Early diagnosis and treatment of mild cognitive impairment and Dementia: An atlas of investigation and diagnosis; is a consultant for PRA International and receives research support from the NIH, Alzheimer's Drug Discovery Foundation, Elan, Janssen Pharmaceuticals Inc., Wyeth, Pfizer Inc, Novartis Pharmaceuticals Ltd, Danone, Avid Radiopharmaceuticals, Merck Serono and for clinical trials.Dr. Bove receives research support from Partners Healthcare, National Multiple Sclerosis Society and the NIH.Dr. De Jager serves as an editorial board member of the Journal of Neuroimmunology; serves on the scientific advisory board for Teva Neuroscience, Genzyme/Sanofi; receives speakers' honoraria from Biogen Idec and Source Healthcare Analytics, LLC; receives research support from Biogen Idec, GlaxoSmithKline, Genzyme/Sanofi, Vertex Pharmaceuticals and the NIH.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Lang served as an advisor for Abbott, Abbvie, Allon Therapeutics, Avanir Pharmaceuticals, Biogen Idec, Boerhinger-Ingelheim, Ceregene, Medtronic, Inc, Merck Serono, Novartis, NeuroPhage Pharmaceuticals, Teva Pharmaceutical Industries Ltd, UCB.; received research support from Brain Canada, Canadian Institutes of Health Research, Edmond J Safra Philanthropic Foundation, Michael J. Fox Foundation, National Parkinson Foundation, Parkinson Society Canada, Tourette Syndrome Association, W. Garfield Weston Foundation; received publishing royalties from Saunders, Wiley-Blackwell, Johns Hopkins Press, Cambridge University Press; served as an expert witness in cases related to the welding industry.

1) Effect of head impacts on diffusivity measures in collegiate contact sport athletes and 2) Topic of the month: Parkinson's and parkinsonism disorders. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Noah Kolb interviews Dr. Thomas McAllister about his paper on effect of head impacts on diffusivity measures in collegiate contact sport athletes. Dr. Adam Numis is reading our e-Pearl of the week about recurrent rhabdomyolysis. In the next part of the podcast Dr. Matt Barrett interviews Dr. Dan Weintraub about management of neuropsychiatric manifestations of Parkinson disease. The participants had nothing to disclose except Drs. McAllister, Numis and Weintraub.Dr. McAllister receives research support from the NIH.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Weintraub serves as an editorial board member of Movement Disorders Journal; serves on the scientific advisory board of Pfizer Inc, Teva Pharmaceutical Industries Ltd., Avanir Pharmaceuticals, Merck Serono, Eli Lilly and Company, Biogen Idec, Lundbeck Inc., UCB, Bristol-Myers Squibb, CHDI Foundation, Inc, ADCS; receives fees from the University of Pennsylvania for licensing of Questionnaire for Impulsive-Compulsive Disorders in Parkinson disease; receives commercial funding for travel from Teva Pharmaceutical Industries Ltd.; gave expert testimony for defense in 2012-2013 in lawsuit related to impulse control disorders in Parkinson disease; receives research support from Novartis, Michael J. Fox Foundation for Parkinson's Research and the NIH.

1) Pretreatment cognitive deficits and treatment effects in childhood epilepsy and 2) Topic of the month: Multiple sclerosis therapy and treatment. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Nick Brenton interviews Dr. Tracy Glauser about his paper on pretreatment cognitive deficits and treatment effects in childhood epilepsy. Lara Marcuse talks about being diagnosed with cancer after listening to Ted Burns discuss his diagnosis in our September 3 podcast. Dr. Adam Numis is reading our e-Pearl of the week about ophthalmologic findings in neurocysticercosis. In the next part of the podcast Dr. Mark Keegan interviews Dr. Douglas Goodin about interferons and copaxone in multiple sclerosis. The participants had nothing to disclose except Drs. Glauser, Numis, Keegan, and Goodin.Dr. Glauser serves on the scientific advisory board for AssureRx Health, Inc.; serves on the speakers' bureau and receives honoraria from Supernus Pharmaceuticals; receives royalties from the publication of the book Pediatric Epilepsy; receives royalty payments for optimization of drug selection software algorithms, AssureRx Health, Inc.; holds stock options in AssureRx Health, Inc.; has patents for optimization of drug selection software algorithms, neurocognitive computing algorithms and suicide prediction algorithms; is a consultant for Supernus Pharmaceuticals, Sunovion Pharmaceuticals, Inc., Eisai, Inc., UCB, Lundbeck Inc., Questcor Pharmaceuticals, Inc, Upsher-Smith, AssureRx Health, Inc.; receives license fees from AssureRx Health, Inc. for optimization of drug selection software algorithms and receives research support from the NIH.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Keegan serves as Chief Editor of eMedicine and receives research support from Terumo BCT.Dr. Goodin receives research support from Novartis; had travel costs reimbursed for occasional community lectures, symposia and/or academic talks sponsored by Bayer Schering Pharma, Teva Pharmaceutical Industries Ltd., Merck Serono. Genzyme and Novartis.

1) Vagus nerve stimulation for the treatment of epilepsy and 2) Topic of the month: Multiple sclerosis therapy and treatment. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Antel Patel interviews Dr. George Morris about his paper on vagus nerve stimulation for the treatment of epilepsy. Dr. Adam Numis is reading our e-Pearl of the week about vitamin B6 and epilepsy. In the next part of the podcast Dr. Mark Keegan interviews Dr. Robert Fox about dimethylfumarate for multiple sclerosis. The participants had nothing to disclose except Drs. Patel, Morris, Numis, Keegan, and Fox.Dr. Patel serves as Book editor for the Journal of Child Neurology; receives research support from UCB and Eisai Inc.Dr. Morris performs clinical care involving vagus nerve stimulation (5% effort) in his practice; serves on the speakers' bureaus of UCB, Cyberonics, Lundbeck, Inc.; is a consultant for UCB, Cyberonics, Lundbeck, Inc.; receives honoraria from UCB, Cyberonics, Lundbeck. Inc; receives research support from UCB, Cyberonics, Lundbeck. Inc.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Keegan serves as Chief Editor of eMedicine and receives research support from Terumo BCT.Dr. Fox serves as an editorial board member of Neurology and Multiple Sclerosis Journal; serves on the scientific advisory board for Biogen Idec, Novartis; is a consultant for Allozyne, Avanir, Biogen Idec, Novartis, Questcor, EMD Serono, and Teva Pharmaceutical Industries Ltd.; receives research support from Novartis, National MS Society and NIH.

1) Cognitive speed of processing training in Parkinson disease and 2) Topic of the month: Multiple sclerosis therapy and treatment. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Binit Shah interviews Dr. Jerri Edwards about her paper on cognitive speed of processing training in Parkinson disease. Dr. Adam Numis is reading our e-Pearl of the week about stiff person syndrome. In the next part of the podcast Dr. Mark Keegan interviews Dr. Jeffrey Cohen about fingolimod therapy for multiple sclerosis. The participants had nothing to disclose except Drs. Edwards, Numis, Keegan, and Cohen.Dr. Edwards receives research support from the NIH.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Keegan serves as Chief Editor of eMedicine and receives research support from Terumo BCT.Dr. Cohen received consulting fees from Novartis and Teva Pharmaceutical Industries Ltd.; receives royalties from the publication of the book Multiple Sclerosis Therapeutics, 4th edition; received research support from the Department of Defense and the NIH.

1) Migraine and structural changes in the brain and 2) Topic of the month: Multiple sclerosis therapy and treatment. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jennifer Bickel interviews Dr. Messoud Ashina about his paper on migraine and structural changes in the brain. Dr. Adam Numis is reading our e-Pearl of the week about manganese neurotoxicity. In the next part of the podcast Dr. Mark Keegan interviews Dr. Paul O' Connor about teriflunomide for the treatment of multiple sclerosis. The participants had nothing to disclose except Drs. Ashima, Numis, Keegan, and O'Connor.Dr. Ashina serves as an Associate Editor of Cephalalgia; serves on the scientific advisory board for The Journal of Headache and Pain; is a consultant for ATI, Allergan, Inc., Amgen and Alder Biopharmaceuticals, Inc.; received honoraria for lecturing from Allergan Inc.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Keegan serves as Chief Editor of eMedicine and receives research support from Terumo BCT.Dr. O'Connor serves on the scientific advisory boards of Novartis Fingolimod Steering Committee, Sanofi-aventis Teriflunomide Steering Committee, BRAVO (laquinimod) study DMC-chairman, Genetech, Inc. Roche, Acetelion Pharmaceuticals Ltd, Receptos, Inc; received honoraria for attending two Advisory board meetings; served on the editorial advisory board for the MS Journal; serves as a consultant for Biogen Idec, Merck Serono, is currently a consultant for Teva Pharmaceutical Industries Ltd., Sanofi-aventis, Novartis; receives research support from Novartis, Sanofi-aventis, Roche, Biogen Idec, and from the MS Society of Canada as National Scientific and Clinical Advisor.

1) GABAB receptor autoantibody frequency in-service serological evaluation and 2) This week's topic: About Ted Burns about being diagnosed with a serious cancer. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Zsofia Hole interviews Dr. Andrew McKeon about his paper on GABAB receptor autoantibody frequency in-service serological evaluation. Dr. Roy Strowd is reading our e-Pearl of the week about Fazio-Londe syndrome. In the next part of the podcast Dr. Alberto Espay interviews Dr. Ted Burns about being diagnosed with a serious cancer and how he has gained insight into what it's like being a patient. The participants had nothing to disclose except Drs. McKeon, Strowd, Espay, and Burns.Dr. McKeon receives research support from the Guthy Jackson Charitable Foundation.Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; is a consultant for Chelsea Therapeutics; serves on the scientific advisory boards for Solvay Pharmaceuticals, Inc., Abbott (now Abbie), Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Merz Pharmaceuticals, LLC, Solstice Neurosciences, and Eli Lilly and Company, USWorldMeds; serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders; serves on the speakers' bureaus of Novartis, UCB, TEVA Pharmaceutical Industries Ltd, American Academy of Neurology, Movement Disorder Society and receives royalties from Lippincott, Williams & Wilkins and Cambridge University Press.Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals.

1) Optic nerve head component responses of multifocal electroretinogram in MS and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Beau Bruce interviews Drs. Teresa and Elliot Frohman about their paper on optic nerve head component responses of multifocal electroretinogram in MS. Dr. Adam Numis is reading our e-Pearl of the week about Terson's syndrome. In the next part of the podcast Dr. Alberto Espay interviews Dr. John Trojanowski about progressive accumulation of tau pathology in patients with Alzheimer disease and how it occurred in a stereotypical manner. The participants had nothing to disclose except Drs. Bruce, Teresa Frohman, Eliot Frohman, Numis, Espay, and Trojanowski.Dr. Bruce is a consultant for Kaiser Permanente of Georgia for the CDC Vaccine Safety Datalink; receives research support from Novartis, Pfizer Inc, TEVA Pharmaceutical Industries, Ltd and the NIH; and was a recipient of the Practice Research Fellowship.Dr. Teresa Frohman serves as an editorial board member of National Multiple Sclerosis Society; is a consultant for Acorda, Novartis; serves on the speakers' bureau of Acorda Therapeutics, Inc., Novartis; receives royalties from the publication of Up-to-Date; received funding for travel from Acorda Therapeutics Inc., Novartis; received research support from the National Multiple Sclerosis Society and the NIH.Dr. Elliot Frohman is a consultant for TEVA Pharmaceutical Industries, Ltd, Acorda Therapeutics, Inc., Novartis, Genzyme Corporation, Abbott; serves on the speakers' bureau of TEVA Pharmaceutical Industries, Ltd, Acorda Therapeutics Inc., Novartis; receives royalties from the publication of Up-to-Date; and received funding for travel from TEVA Pharmaceutical Industries, Ltd, Acorda Therapeutics Inc., Novartis.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; is a consultant for Chelsea Therapeutics; serves on the scientific advisory boards for Solvay Pharmaceuticals, Inc., Abbott (now Abbie), Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Merz Pharmaceuticals, LLC, Solstice Neurosciences, and Eli Lilly and Company, USWorldMeds; serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders; serves on the speakers' bureaus of Novartis, UCB, TEVA Pharmaceutical Industries Ltd, American Academy of Neurology, Movement Disorder Society and receives royalties from Lippincott, Williams & Wilkins and Cambridge University Press.Dr. Trojanowski serves as an Associate Editor for Alzheimer & Dementia; received research support from The Marian S. Ware Alzheimer Program, Benaroya and the NIH; holds 14 patents that may accrue revenue: US Patent 5,281,521, issued 25 Jan 1994: US Patent 5,580,898, issued 3 Dec 1996; US Patent 5,601,985, issued 11 Feb 1997; US Patent 5,733,734, issued 31 Mar 1998; US Patent 5,792,900, issued 11 Aug 1998; US Patent 5,849,988, issued 15 Dec 1998: US Patent 6,214,334, issued 10 Apr 2001; US Patent 6,358,681, issued 19 Mar 2002; US Patent 6,727,075, issued 27 Mar 2004; US Patent 7,011,827, issued 14 Mar 2006; Penn 0652, K1828, filed 5 Aug 1998; Penn L1986, Filed 13 Nov 1998; Penn R3868 (UPN-4439), filed 28 Feb 2005 and Penn S-4018, DB&R 46406- 217282, filed 22 Nov 2005: Treatment of Alzheimer's and Related Diseases with an Antibody and may accrue revenue in the future on patents submitted by the University of Pennsylvania as co-Inventor and received revenue from the sale of Avid to Eli Lilly and Company as co-inventor on imaging related patents submitted by the University of Pennsylvania while receiving research support from the NIH, Bristol-Myers Squibb, AstraZeneca and several non-profits.

1) Evidence-based guideline: Treatment of tardive syndromes and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Waugh interviews Drs. Roongroj Bhidayasiri and Gary Gronseth about the AAN evidence-based guideline on treatment of tardive syndromes. Dr. Roy Strowd is reading our e-Pearl of the week about CTA spot sign. In the next part of the podcast Dr. Alberto Espay interviews Dr. Marsel Mesulam about his H. Houston Merritt Lecture on the selective cognitive impairments and distinct neuropathological entities of the primary progressive aphasias. The participants had nothing to disclose except Drs. Bhidayasiri, Gronseth, Strowd, Espay and Mesulam.Dr. Bhidayasiri served as Editor-in-Chief for The Thai Journal of Neurology; serves on the scientific advisory board for Ministry of Public Heath, Thailand and Excellence Network; serves as Director of Chulalongkorn Center of Excellence on Parkinson's Disease and Related Disorders, Thai Red Cross Society; received funding for trips from BL Hua, GlaxoSmithKline, Medtronic, Inc., Roche; serves on the speakers' bureau of Abbott, BL Hua, Boehringer-Ingelheim, GlaxoSmithKline, Medtronic, Inc., Novartis, Roche; receives royalties from the publication of the books Neurological Differential diagnosis, International Neurology, Movement Disorders: A video atlas; receives research support from Abbott, Immunocal Thailand, Chulalongkorn University, Bangkok, Thailand, Thailand Research Fund and Thai Red Cross Society.Dr. Gronseth serves on the editorial board of Neurology Now and receives research support from the American Academy of Neurology.Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; is a consultant for Chelsea Therapeutics; serves on the scientific advisory boards for Solvay Pharmaceuticals, Inc., Abbott (now Abbie), Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Merz Pharmaceuticals, LLC, Solstice Neurosciences, and Eli Lilly and Company, USWorldMeds; serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders; serves on the speakers' bureaus of Novartis, UCB, TEVA Pharmaceutical Industries Ltd, American Academy of Neurology, Movement Disorder Society and receives royalties from Lippincott, Williams & Wilkins and Cambridge University Press.Dr. Mesulam serves on the scientific advisory board for Cure Alzheimer Fund and Association on Frontotemporal Dementia; serves as an editorial board member of Brain, Annals of Neurology, Human Brain Mapping, Journal of Cognitive Neuroscience; receives royalties from the publication of the book Principles of Behavioral and Cognitive Neurology and receives research support from the NIH.

1) Rasmussen's encephalitis treated with natalizumab and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. John Mytinger interviews Prof. Heinz Wiendl about his paper on Rasmussen's encephalitis treated with natalizumab. Dr. Roy Strowd is reading our e-Pearl of the week about watching for Whipple's: Oculomasticatory myorhythmia. In the next part of the podcast Dr. Alberto Espay interviews Dr. Pooja Khatri on intra-arterial therapy being used as standard treatment for acute stroke. The participants had nothing to disclose except Prof. Wiendl, Drs. Strowd, Espay and Khatri.Prof. Wiendl received honoraria for travel to attend meetings from Bayer Schering Pharma, Biogen Idec, Elan Corporation, Sanofi- Aventis, Schering-Plough Corp., Merck Serono, Teva Pharmaceuticals Industries Ltd.; has served as a consultant or is currently a consultant for Merck Serono, Medac, Inc, Sanofi-aventis, Biogen Idec, Bayer Schering Pharma, Novartis, Teva Pharmaceuticals Industries Ltd., Novo Nordisk; receives research support from Bayer Schering Pharma, Biogen Idec, Elan Corporation, Sanofi-aventis, Merck Serono, Teva Pharmaceuticals Industries Ltd., Novartis, Medac, Inc, Genzyme and Novo Nordisk.Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; is a consultant for Chelsea Therapeutics; serves on the scientific advisory boards for Solvay Pharmaceuticals, Inc., Abbott (now Abbie), Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Merz Pharmaceuticals, LLC, Solstice Neurosciences, and Eli Lilly and Company, USWorldMeds; serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders; serves on the speakers' bureaus of Novartis, UCB, TEVA Pharmaceutical Industries Ltd, American Academy of Neurology, Movement Disorder Society and receives royalties from Lippincott, Williams & Wilkins and Cambridge University Press.Dr. Khatri received funding for a trip from Genetech, Inc.; provided expert witnessing for stroke cases over last two years; receives research support from Penumbra, Inc and the NIH.

1) Development and validation of a clinical guideline for diagnosing blepharospasm and 2) Topic of the month: AAN Plenary Sessions. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Binit Shah interviews Dr. Giovanni Defazio about his paper on development and validation of a clinical guideline for diagnosing blepharospasm. Dr. Roy Strowd is reading our e-Pearl of the week about iatrogenic botulism. In the next part of the podcast Dr. Alberto Espay interviews Dr. Salvatore DiMauro about his Robert Wartenberg Lecture on Mitochondrial encephalomyopathies: 50 years on. The participants had nothing to disclose except Drs. Defazio, Strowd, Espay and DiMauro.Dr. Defazio receives research support from the Italian Ministry of University and Comitato Promotore Telethon.Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; is a consultant for Chelsea Therapeutics; serves on the scientific advisory boards for Solvay Pharmaceuticals, Inc., Abbott (now Abbie), Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Merz Pharmaceuticals, LLC, Solstice Neurosciences, and Eli Lilly and Company, USWorldMeds; serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders; serves on the speakers' bureaus of Novartis, UCB, TEVA Pharmaceutical Industries Ltd, American Academy of Neurology, Movement Disorder Society and receives royalties from Lippincott, Williams & Wilkins and Cambridge University Press.Dr. DiMauro serves as an editorial board member of Muscle and Nerve, Neuromuscular Disorders, Acta Myologica, MedLink Neurology; serves on the scientific advisory board for Telethon Italia; receives research support from the Muscular Dystrophy Association, Marriott Mitochondrial Disorder Clinical Research Fund and the NIH.